Regulation · United States

What is
peptide therapy?

A phrase medical journals use for treating patients with peptide drugs. What US law says about approved medicines, compounded drugs and research-use-only products, in the regulators’ own words, as of November 2026.

Short answerRegulation · 8 min read · Updated 21 Nov 2026

Peptide therapy is a phrase used in medical journals for treating patients with peptide drugs, approved or not. In the US, the prescription route means either an FDA-approved product, or a drug compounded by a licensed pharmacy, physician or outsourcing facility. FDA says “Compounded drugs are not FDA-approved.” Research-use-only products belong to neither group.

Key takeaways

  • Medical journals use the phrase; sections 503A and 503B of US drug law do not, and sort products by who made them, for whom, and what was checked first.
  • FDA (page current as of 16 September 2025): “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
  • Section 503A requires an identified individual patient and a valid prescription order; section 503B covers outsourcing facilities that register with FDA and follow current good manufacturing practice.
  • In a notice filed on 28 October 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding with six named peptides in ten listed circumstances; the notice calls the policy a draft that is not binding, and it is not an approval.

01What is peptide therapy?

“Peptide therapy” is a phrase used in medical journals for treating patients with peptide drugs. A 2026 review in Sports Medicine applies it to “approved and unapproved” peptides alike. The two sections of US law behind this page, 503A and 503B, do not use the phrase. They sort a product by who made it, for whom, and what was checked first.

Three lanes matter for this page. Only the first two involve a prescription.

Route 1

Approved medicine

A product FDA has approved for the uses on its label. FDA says people “rely on FDA’s drug approval process for verification of safety, effectiveness and quality”.

Route 2

Compounded on prescription

A licensed pharmacist or physician combines, mixes or alters ingredients to make a medication for an individual patient. FDA: “Compounded drugs are not FDA-approved.”

Not a prescription route

Research use only

A product labelled for laboratory research. It is not made under section 503A or 503B, and FDA has not reviewed it for use in people.

This page describes US rules. The UK and Australia regulate differently: see the UK and Australia.

02What does “compounded” mean under sections 503A and 503B?

HHS’s notice of 30 October 2026 gives the definition. Compounding is “generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient”.

Section 503A covers a licensed pharmacist in a state-licensed pharmacy or federal facility, and a licensed physician. The drug must be compounded “for an identified individual patient based on the receipt of a valid prescription order”. When the section’s conditions are met, three requirements do not apply: FDA approval before marketing, labelling with adequate directions for use, and current good manufacturing practice (CGMP).

Section 503B covers outsourcing facilities, a category created in 2013. They register with FDA and stay subject to CGMP. The statute says an outsourcing facility “may or may not obtain prescriptions for identified individual patients”.

Who can prescribe. Section 503A refers to a prescription order “made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs”. State law decides which professions that covers.

Which ingredients. Under 503A, a bulk drug substance must comply with a USP or NF monograph, or be a component of an FDA-approved drug, or appear on a list FDA sets by regulation, the 503A bulks list. The interim categories FDA uses while it builds that list are on Category 1, 2 and 3.

RouteWho makes it, and for whomReviewed by FDA before marketing?Quality standard and oversight
Approved medicineA manufacturer, for the patients and uses on the labelFDA: people “rely on FDA’s drug approval process for verification of safety, effectiveness and quality”CGMP applies
Compounded, section 503AA licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, for an identified patient with a valid prescriptionFDA: “Compounded drugs are not FDA-approved”Exempt from CGMP when the section’s conditions are met. FDA: state boards of pharmacy “have primary responsibility for the day-to-day oversight” of these pharmacies
Compounded, section 503BAn outsourcing facility registered with FDA, which “may or may not obtain prescriptions for identified individual patients”FDA: “Compounded drugs are not FDA-approved”; an outsourcing facility’s products are compounded drugsCGMP applies. FDA: such facilities are “primarily overseen by FDA and inspected by FDA according to a risk-based schedule”
Research-use-only productA seller, with labelling for laboratory researchNot reviewed for use in peopleFDA judges intended use by “the objective intent of the persons legally responsible for the labeling”, shown for example by “labeling claims, advertising matter, or oral or written statements” (21 CFR 201.128)

03Is peptide therapy FDA approved? What FDA says

FDA answers for the product, not for the phrase. In its words (page current as of 16 September 2025): “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

An approval belongs to one product and the uses on its label. Wegovy, for example, is a prescription medicine that contains the peptide semaglutide. Its US label covers, among other uses, reducing excess body weight in adults and children aged 12 and over with obesity, and in adults with overweight who have at least one weight-related condition, alongside a reduced-calorie diet and physical activity. Research-grade material sold under the same name is not that medicine.

The six peptides in HHS’s October 2026 draft policy (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) are covered as bulk drug substances “not a component of an FDA-approved drug product”. The policy is about enforcement. It is not an approval.

04What changed in US peptide policy from 2023 to 2026?

  1. Sep 2023Category 2

    FDA placed BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon in Category 2 of its interim list for 503A compounding, the category for substances that “may present significant safety risks”.

  2. 16–22 Apr 2026Nominations withdrawn, meeting announced

    A Federal Register notice of 16 April announced an advisory committee meeting for 23 and 24 July. The six peptides’ time in Category 2 ended on 22 April; FDA’s page lists them as “withdrawn by the nominators”. HHS later wrote that “neither the placement nor the removal changed” their status under section 503A.

  3. 23–24 Jul 2026Advisory committee

    FDA’s Pharmacy Compounding Advisory Committee discussed seven peptides. For the six above, HHS records that FDA’s drug centre “recommended against listing” and that the committee “voted in favor”. FDA describes such votes as “non-binding recommendations”. Detail: the 2026 advisory vote.

  4. 28–30 Oct 2026HHS draft policy

    HHS said it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding with one of the six, in ten listed circumstances. They include a patient-specific prescription and a single active ingredient. The notice, filed on 28 October and published on 30 October, calls the policy a draft that “is not binding on HHS or the public”. Detail: the HHS policy, explained.

  5. NextRulemaking

    The policy applies until a peptide “is addressed in a final rule as being included or not included on the 503A bulks list”. HHS says it may revisit the interim policy “if, among other things, a safety signal or product quality issue arises”. Dated updates: regulatory changelog.

05Is peptide therapy safe? What regulators say

Each statement below is about one route, in the regulator’s own words, with its date. None is a judgement about a particular patient.

Approved medicines. Safety information is part of the approved label. Wegovy’s label, for example, carries a boxed warning: semaglutide causes thyroid C-cell tumours in rodents, and “It is unknown whether WEGOVY causes thyroid C-cell tumors” in humans (label effective 18 June 2026).

Compounded drugs. FDA (page current as of 16 September 2025): “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” It adds that poor compounding practices “can result in serious drug quality problems” and that this “can lead to serious patient injury and death”. For compounded versions of two approved peptide medicines, FDA had received 990 adverse-event reports for semaglutide and more than 730 for tirzepatide as of 31 May 2026. FDA attaches three limits to those figures: reports are likely under-counted, because state-licensed pharmacies that are not outsourcing facilities are not required to submit them; many appear consistent with events seen with the approved products; and it is “not always possible to determine if the adverse event directly resulted from use of the drug”.

BPC-157, one of the six peptides in HHS’s draft policy. FDA staff’s July 2026 review found “insufficient clinical safety information to characterize the safety profile”, and said that as a peptide “administered through a parenteral or nasal” route it “may pose a significant risk for immunogenicity”. FDA’s compounding page (current as of 22 April 2026) says of BPC-157 that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. HHS’s policy text says the policy “advances patient choice and freedom while appropriately protecting patient safety”, and it has compounders report serious adverse events to FDA.

Research-use-only products. HHS’s policy text names one aim as to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients”. FDA says it has warned companies that “illegally sold” unapproved GLP-1 drugs “falsely labeled ‘for research purposes’ or ‘not for human consumption’” directly to consumers, and describes those products as “of unknown quality” that “may be harmful to their health” (page current as of 1 October 2026).

More: are peptides safe and peptide side effects.

06What does a regulator check on each route?

The routes differ in what is checked, by whom, and when.

Approved medicine: the product.

Before marketing, FDA’s approval process verifies safety, effectiveness and quality for the uses on the label.

Section 503A: the prescription and the licence.

An identified patient, a valid prescription, and a licensed pharmacist or physician. State boards of pharmacy have primary day-to-day oversight.

Section 503B: the facility.

Registration with FDA, CGMP, and FDA inspection on a risk-based schedule. The products are still compounded drugs, which are not FDA-approved.

Research use only: the intended use.

FDA looks at “the objective intent” of whoever is responsible for the labelling, shown by claims, advertising and statements. More: what “research use only” means.

What we don’t know.

  • Whether FDA will add any of the six peptides to the 503A bulks list. HHS’s notice says future rulemakings “may propose adding some or all of these peptides”.
  • How long the interim policy will stand. HHS says it may revisit it, in whole or in part.

How evidence differs between approved and unapproved peptides: do peptides work? and peptides graded by evidence. Rule changes, once a week: the 6:00 brief.

This is a plain-English summary of public documents, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. 21 U.S.C. 353a. Pharmacy compounding (FD&C Act section 503A). US Code, current text via Cornell LII; read 21 Nov 2026. www.law.cornell.edu/uscode/text/21/353a
  2. 21 U.S.C. 353b. Outsourcing facilities (FD&C Act section 503B). US Code, current text via Cornell LII; read 21 Nov 2026. www.law.cornell.edu/uscode/text/21/353b
  3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA page, content current as of 16 Sep 2025; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/compounding-and-fda…
  4. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability (91 FR 68526, FR Doc. 2026-22192; filed 28 Oct 2026). Federal Register notice, 30 Oct 2026; text read on govinfo 21 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  5. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (policy text, ten circumstances, Appendix A). Policy document, Oct 2026. hhs.gov returned 403 on 21 Nov 2026; read on the Internet Archive capture of 11 Nov 2026, the newest. web.archive.org/web/20261111210456/https://www.hhs.gov/sites…
  6. U.S. Department of Health and Human Services. The same policy with Appendix B (Category 2 dates, drug-centre and committee positions for each peptide). Read on the Internet Archive capture of 15 Nov 2026, the newest readable capture. web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  7. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  8. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (Categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  9. Federal Register. FR Doc. 2026-07361 (91 FR 20465), Pharmacy Compounding Advisory Committee; notice of meeting (23–24 July 2026). Notice, 16 Apr 2026; record read 21 Nov 2026. www.federalregister.gov/documents/2026/04/16/2026-07361/phar…
  10. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current as of 6 Aug 2026; read 21 Nov 2026. www.fda.gov/advisory-committees/advisory-committee-calendar/…
  11. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 21 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  12. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances (PDF p. 43). Advisory committee briefing, memo dated 11 May 2026; read 21 Nov 2026. www.fda.gov/media/193343/download
  13. Novo Nordisk. Wegovy (semaglutide) US prescribing information: boxed warning and section 1. DailyMed label, effective 18 Jun 2026; read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  14. 21 CFR 201.128. Meaning of “intended uses”. Code of Federal Regulations (86 FR 41401, 2021), current eCFR text; read 21 Nov 2026. www.ecfr.gov/current/title-21/section-201.128
  15. Mendias CL, Awan TM. [Narrative review of 12 approved and unapproved peptides marketed directly to patients.] Sports Med, 2026;56(8):1921–1935. PMID 41966639 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/41966639/
  16. Mayfield CK, Bolia IK, Feingold CL, et al. [Narrative review of peptide therapy for orthopaedic and sports medicine physicians.] Am J Sports Med, 2026;54(1):223–229. PMID 41476424 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/41476424/

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is peptide therapy FDA approved?

FDA’s wording (page current as of 16 September 2025): “Compounded drugs are not FDA-approved.” Approved peptide medicines are approved product by product, for the uses on each label.

What is the difference between 503A and 503B compounding?

Section 503A covers licensed pharmacists and physicians compounding for an identified patient with a valid prescription. Section 503B covers outsourcing facilities, which register with FDA, follow current good manufacturing practice, and “may or may not obtain prescriptions for identified individual patients”.

What does the October 2026 HHS peptide policy cover?

HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding with six named peptides in ten listed circumstances. The Federal Register notice calls it a draft that is not binding. It is not an approval.

Who can prescribe a compounded peptide drug?

Section 503A refers to a prescription order “made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs”. State law decides which professions that covers.

Is a research-use-only peptide part of peptide therapy?

Not in the sense used on this page. Sections 503A and 503B cover drugs compounded by licensed pharmacists, physicians and outsourcing facilities. FDA judges a product labelled for research by its intended use, under 21 CFR 201.128.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page